SCHEMBL714303

SCHEMBL714303

CC(Oc1ccccc1)c1csc(Nc2ccc(S(=O)(=O)Nc3nccs3)cc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.63
KMT2A Q03164 6/20 0.63
PKM P14618 2/20 0.53
SCN1A P35498 2/20 0.52
SCN5A Q14524 2/20 0.52
SCN8A Q9UQD0 2/20 0.52
SCN1B Q07699 1/20 0.52
POLB P06746 5/20 0.52
SCN3A Q9NY46 3/20 0.52
CCNT1 O60563 1/20 0.51
CDK9 P50750 1/20 0.51
SCN9A Q15858 2/20 0.50
SCN4A P35499 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN10A Q9Y5Y9 1/20 0.50
EGFR P00533 1/20 0.50
KDR P35968 1/20 0.50
ALDH1A1 P00352 1/20 0.49
KDM4E B2RXH2 1/20 0.49
USP2 O75604 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714725 0.83 SCN8A (0.60) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL710350 0.80 PKM (0.54) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL3640394 0.79 ADRB2 (0.55) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL712318 0.79 MEN1 (0.63) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL712533 0.78 ADRB2 (0.59) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL711626 0.78 ALDH1A1 (0.60) MEN1KMT2APKMPOLBCCNT1
SCHEMBL711654 0.77 SCN1A (0.59) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL712620 0.76 KMT2A (0.57) MEN1KMT2APKMCCNT1CDK9
SCHEMBL713201 0.76 PKM (0.48) MEN1KMT2APKMSCN1ASCN5A
SCHEMBL713846 0.76 SCN1A (0.56) MEN1KMT2APKMSCN1ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A MEN1 4426/4885KMT2A 1945/4885PKM 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.